CD133+ colon cancer cells are more interactive with the tumor microenvironment than CD133− cells

Experimental data indicate that colorectal cancer cells with CD133 expression exhibit enhanced tumorigenicity over CD133-negative (CD133−) cells. We hypothesized that CD133-positive (CD133+) cells, compared with CD133−, are more tumorigenic because they are more interactive with and responsive to their stromal microenvironment. Freshly dissected and dissociated cells from a primary colon cancer were separated into carcinoma-associated fibroblasts (CAF) and the epithelial cells; the latter were further separated into CD133+ and CD133− cells using fluorescence-activated cell sorter. The CD133+ cells formed large tumors in non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice, demonstrating the phenotypic cellular diversity of the original tumor, whereas CD133− cells were unable to sustain significant growth. Affymetrix gene array analyses using t-test, fold-change and multiple test correction identified candidate genes that were differentially expressed between the CD133+ vs CD133− cells. RT-PCR verified differences in expression for 30 of the 46 genes selected. Genes upregulated (+ vs – cells) included CD133 (9.3-fold) and CXCR4 (4-fold), integrin β8 and fibroblast growth factor receptor 2. The CAF highly express the respective ligands: stromal-derived factor-1 (SDF-1), vitronectin and FGF family members, suggesting a reciprocal relationship between the CD133+ and CAF cells. SDF-1 caused an increase in intracellular calcium in cells expressing both CD133 and CXCR4, confirming functional CXCR4. The CD133+/CXCR4+ phenotype is increased to 32% when the cells are grown in suspension compared with only 9% when the cells were allowed to attach. In Matrigel 3-D culture, the CD133+/CXCR4+ group treated with SDF-1 grew more colonies compared with vehicle, as well as significantly larger colony sizes of tumor spheres. These data demonstrate proof of principle that the enhanced tumorigenic potential of CD133+, compared with CD133−, cells is due to their increased ability to interact with their neighboring CAF.

[1]  K. Iczkowski,et al.  Cyclophosphamide-Induced Cystitis Increases Bladder CXCR4 Expression and CXCR4-Macrophage Migration Inhibitory Factor Association , 2008, PloS one.

[2]  I. Ng,et al.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells. , 2007, Gastroenterology.

[3]  β8 integrin regulates neurogenesis and neurovascular homeostasis in the adult brain , 2009, Journal of Cell Science.

[4]  T. Tot Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. , 2002, European journal of cancer.

[5]  C. Townsend,et al.  Gastrointestinal hormone receptors in primary human colorectal carcinomas. , 2005, The Journal of surgical research.

[6]  K. Mimori,et al.  Biological and Genetic Characteristics of Tumor-Initiating Cells in Colon Cancer , 2008, Annals of Surgical Oncology.

[7]  Thomas Kirchner,et al.  The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer , 2009, The Journal of pathology.

[8]  M. Ziol,et al.  Stromal Cell–Derived Factor-1/Chemokine (C-X-C Motif) Ligand 12 Stimulates Human Hepatoma Cell Growth, Migration, and Invasion , 2007, Molecular Cancer Research.

[9]  Giulio Gabbiani,et al.  The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. , 2004, The International journal of developmental biology.

[10]  R Y Tsien,et al.  Practical design criteria for a dynamic ratio imaging system. , 1990, Cell calcium.

[11]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[12]  D. Neal,et al.  CD133, a novel marker for human prostatic epithelial stem cells , 2004, Journal of Cell Science.

[13]  N. Maitland,et al.  Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.

[14]  J. Kearney,et al.  AC133, a novel marker for human hematopoietic stem and progenitor cells. , 1997, Blood.

[15]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[16]  Jianren Gu,et al.  CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity , 2007, International journal of cancer.

[17]  R. Warnke,et al.  A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. , 1997, Blood.

[18]  Ed Roos,et al.  The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. , 2003, Cancer research.

[19]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[20]  M. Wong,et al.  Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. , 2010, Gastroenterology.

[21]  Aleksandar Dakic,et al.  Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells , 2007, Science.

[22]  Beverly A. Teicher,et al.  CXCL12 (SDF-1)/CXCR4 Pathway in Cancer , 2010, Clinical Cancer Research.

[23]  M. Florek,et al.  New Insights into the Cell Biology of Hematopoietic Progenitors by Studying Prominin-1 ( CD 133 ) , 2008 .

[24]  W. Huttner,et al.  A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. , 2000, Human molecular genetics.

[25]  Douglas B. Evans,et al.  Cancer-associated stromal fibroblasts promote pancreatic tumor progression. , 2008, Cancer research.

[26]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[27]  P. Hein,et al.  Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium , 2000, Breast Cancer Research.

[28]  Louis Vermeulen,et al.  Wnt activity defines colon cancer stem cells and is regulated by the microenvironment , 2010, Nature Cell Biology.

[29]  M. Imamura,et al.  CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. , 2004, Molecular cancer therapeutics.

[30]  A. Navarro,et al.  Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. , 2010, European journal of cancer.

[31]  Michael F. Clarke,et al.  Phenotypic characterization of human colorectal cancer stem cells , 2007, Proceedings of the National Academy of Sciences.

[32]  S. Rutella,et al.  Cells with Characteristics of Cancer Stem/Progenitor Cells Express the CD133 Antigen in Human Endometrial Tumors , 2009, Clinical Cancer Research.

[33]  M. Todaro,et al.  IL-4-mediated drug resistance in colon cancer stem cells , 2008, Cell cycle.

[34]  Ian A. White,et al.  CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. , 2008, The Journal of clinical investigation.

[35]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[36]  L. Coussens,et al.  Tumor stroma and regulation of cancer development. , 2006, Annual review of pathology.

[37]  M. Florek,et al.  New Insights into the Cell Biology of Hematopoietic Progenitors by Studying Prominin-1 (CD133) , 2007, Cells Tissues Organs.

[38]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[39]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[40]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[41]  H. Frucht,et al.  Cholinergic receptor up-regulates COX-2 expression and prostaglandin E(2) production in colon cancer cells. , 2000, Carcinogenesis.

[42]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[43]  M. Todaro,et al.  Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity , 2008, Proceedings of the National Academy of Sciences.

[44]  K. Rubin,et al.  Vitronectin in colorectal adenocarcinoma--synthesis by stromal cells in culture. , 1994, Experimental cell research.

[45]  D. Horst,et al.  CD133 expression is an independent prognostic marker for low survival in colorectal cancer , 2008, British Journal of Cancer.

[46]  Mark Shackleton,et al.  Efficient tumour formation by single human melanoma cells , 2008 .

[47]  Ling Xia,et al.  Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. , 2009, Cancer research.

[48]  Lei Du,et al.  CD44 is of Functional Importance for Colorectal Cancer Stem Cells , 2008, Clinical Cancer Research.